Twelve years of Make in India, and the growth rate covers three
Manufacturing GVA grew at 10.88 per cent a year - measured from 2022-23, on a national accounts series that was itself only documented three days ago.
What happened
- Make in India completed twelve years; launched 25 September 2014, expanded as Make in India 2.0 across 27 sectors.
- Manufacturing GVA CAGR 10.88% (2022-23 to 2025-26, constant prices); manufacturing IIP +7.0% April-July 2026.
- Electronics ~Rs 1.9 lakh cr to ~Rs 13.11 lakh cr; mobile phones ~Rs 18,000 cr to ~Rs 6.27 lakh cr.
- Defence: Rs 46,429 cr to Rs 1.78 lakh cr. Steel: 81.7 to 170.0 MT. Vehicles: 31.03 million units.
- A pilot plant for Nd-Fe-B rare earth permanent magnets was set up at ARCI Hyderabad in March 2026.
For Prelims
- Make in India: launched 25 September 2014; Make in India 2.0 covers 27 sectors - 15 manufacturing and 12 services. Guiding phrase: Minimum Government, Maximum Governance.
- The supporting instruments named: NSWS, PLI, PM GatiShakti and the India Industrial Land Bank.
- Electronics: ~Rs 13.11 lakh crore in 2025-26, up 15.8% year on year. India is the world's second-largest mobile phone manufacturer by volume.
- Pharma: 3rd globally by volume, 11th by value; turnover Rs 4,71,898 crore in 2024-25, 9.5% CAGR since 2020-21. Medical devices up 48.2% to Rs 41,500 crore.
- Railways: 54,809 coaches over 2014-24; 1,674 locomotives and 6,677 LHB coaches in 2025-26. LHB coaches are lighter, safer and anti-telescopic.
- Rare earth magnets: a pilot plant for Nd-Fe-B (Neodymium-Iron-Boron) at ARCI Hyderabad, March 2026 - essential for EVs, renewables and electronics.
- Advanced pharma products named: Trastuzumab Emtansine (world's first biosimilar antibody-drug conjugate for breast cancer), Docaravimab-Miromavimab (world's first anti-rabies monoclonal antibody combination), Miqnaf and Desidustat.
- The base-year catch: the 10.88% CAGR is on the 2022-23 national accounts series, released 27 February 2026 and documented only on 21 September 2026.
For UPSC: The single most useful manufacturing document of the year, because it carries 2014-15 baselines sector by sector rather than headline claims. Use it on industrial policy and Make in India, on electronics and semiconductor manufacturing where the mobile-phone concentration is the caveat, and on defence indigenisation, where Rs 1.78 lakh crore is the number to quote.
What it is NOT: The headline CAGR covers 2022-23 to 2025-26 - three years of a twelve-year programme - so it cannot be read as Make in India's record. No manufacturing share of GDP is given for any year, which is the standard measure of whether manufacturing is actually gaining ground and the one the programme set a target for. No employment figures appear anywhere, for any sector. Production values are nominal, so the electronics and pharma multiples include price inflation that the release does not strip out. Value added versus assembly is not distinguished for electronics, so how much of Rs 13.11 lakh crore is domestic content is unknown. And no import or export figures are given, so import substitution - the whole point - is not demonstrated.
For Mains
Syllabus: GS3.8 · GS3.1 · Linkage L2
Anchor
Make in India turns twelve, and the growth rate the backgrounder leads with covers three of those years. Manufacturing GVA grew at a compound 10.88 per cent between 2022-23 and 2025-26, on the national accounts series with a 2022-23 base that MoSPI documented only on 21 September.
Substantiation (data)
The sectoral series is more informative than the aggregate. Electronics rose nearly sevenfold to about Rs 13.11 lakh crore, but mobile phones went from about Rs 18,000 crore to about Rs 6.27 lakh crore - roughly 54 per cent of the entire electronics increase came from one product category. Defence production nearly quadrupled to Rs 1.78 lakh crore, crude steel doubled to 170 million tonnes, and railway coach output rose about two-thirds by annual average.
Position
The deepening is the part worth crediting, because it is the part that is hardest. A Nd-Fe-B rare earth magnet pilot plant at ARCI, semiconductors for space applications, and complex biologics such as a first-in-class biosimilar antibody-drug conjugate are capabilities in inputs and strategic materials rather than in final assembly - which is where import dependence actually sits.
Counterpoint
Concentration cuts the other way too. An electronics story that is mostly mobile phones is exposed to one product cycle and one set of global buyers, and the pharma pair - third by volume, eleventh by value - is the same caution in different form: India makes a great deal of medicine and captures a small share of what medicine is worth.
Problematisation
Two things a twelve-year retrospective should contain are missing. There is no manufacturing share of GDP for any year, which is the measure the programme was launched against, and there are no employment figures at all. Production values are also nominal, so the multiples carry price inflation the release never strips out.
Conclusion
Read the sectoral tables and treat the headline with care. Indian manufacturing has demonstrably deepened into components, strategic materials and defence over twelve years; whether it has grown as a share of the economy is a question this document does not answer and does not ask.
Deploys into: Industrial policy and Make in India · Electronics and semiconductor manufacturing · Defence indigenisation · Reading growth rates and base years
PIB Backgrounder · 2026-09-24 · PRID 2314447 · PIB source ↗